Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection
| Autor: | Ana Royuela, Gema M Lledó, Itziar Carrasco, Ana Arias, Laura Benítez-Gutiérrez, Carmen de Mendoza, Valentín Cuervas-Mons, Silvia Requena |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Cirrhosis Hepatitis C virus Immunology HIV Infections medicine.disease_cause Gastroenterology Antiviral Agents 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Fibrosis Internal medicine medicine Immunology and Allergy Humans 030212 general & internal medicine business.industry Coinfection Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Infectious Diseases Treatment Outcome Liver Population study Elasticity Imaging Techniques 030211 gastroenterology & hepatology Female Hepatic fibrosis Viral hepatitis business |
| Zdroj: | AIDS (London, England). 32(16) |
| ISSN: | 1473-5571 |
| Popis: | BACKGROUND Treatment with direct-acting antivirals (DAA) eradicates hepatitis C virus (HCV) from most chronic carriers. Information on regression of liver fibrosis and the influence of HIV is scarce in cured patients. METHODS All consecutive HCV-infected individuals treated with DAA at our institution were examined. Hepatic elastography was performed at baseline and at the time of SVR12. Liver fibrosis regression was defined as a shift from advanced fibrosis (Metavir F3-F4) to null-mild fibrosis (F0-F2) and/or a reduction greater than 30% kPa. AST to platelet ratio index (APRI) and fibrosis 4 (FIB-4) scores were calculated in parallel. RESULTS A total of 260 patients were treated with DAA. All but 14 achieved SVR12 and represented the study population. HIV confection was present in 42%. At baseline, 57.2% had advanced liver fibrosis with a median of 11 kPa, FIB-4 of 2.4, and APRI of 0.95. At the time of SVR12, a median reduction of 2.1 kPa (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|